Analysis
Bambusa Therapeutics priced an upsized initial public offering of 10,555,555 shares of common stock at $16.00 per share late on October 29, 2026, for expected gross proceeds of $168,888,880, with shares set to begin trading on the Nasdaq Global Select Market under the ticker BBTX on October 30. The offering was upsized from an original 9.38 million shares and priced at the midpoint of its marketed range, according to IPO-tracking site IPOScoop, which also put Bambusa's market cap at pricing at about $815.7 million.
What Bambusa Therapeutics does
Bambusa is a clinical-stage biopharmaceutical company developing long-acting, precision bispecific antibodies for immunology and inflammation, incorporated in Delaware in March 2024 and headquartered in Boston. Its lead program, BBT001, targets IL-4Ra and IL-31 and is in a global Phase 1 trial for moderate-to-severe atopic dermatitis and other inflammatory skin diseases. A second program, BBT002, targets IL-4Ra and IL-5 for Type 2 inflammatory disorders including COPD, which is in Phase 1 and Phase 1/2a trials, plus a Phase 2a trial in China for chronic rhinosinusitis with nasal polyps. Two preclinical programs, BBT003 and BBT004, target inflammatory bowel disease and autoantibody-driven autoimmune disease respectively. The company was co-founded by chief executive Shanshan Xu and chief development officer Thang Ho, and it acquired its lead assets from a BioNTech subsidiary formerly known as Biotheus. Bambusa reported a net loss of $48.7 million for the 12 months ended June 30, 2026.
Bambusa's funding history
Bambusa's pre-IPO financing:
“Its lead program, BBT001, targets IL-4Ra and IL-31 and is in a global Phase 1 trial for moderate-to-severe atopic dermatitis and other inflammatory skin diseases.”
- Series A, February 2025 -- approximately $90M, oversubscribed, led by new investor RA Capital Management.
- Total private financings before the IPO -- $136.1M in gross proceeds, with backers including ATHOS, BVF Partners, Dawn Biopharma (a platform controlled by KKR), INCE Capital, RA Capital, Salvia, Janus Henderson Investors, Redmile Group, Invus and ADAR1 Capital Management.
RA Capital remains a principal shareholder heading into the public markets.
Who underwrote Bambusa's IPO
BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are acting as joint book-running managers on the offering. Underwriters also hold a 30-day option to purchase up to 1,583,333 additional shares at the IPO price, less discounts, which could lift total proceeds further if exercised. The deal is expected to close on November 2, 2026.
Biotech IPO market and comparable debuts
Bambusa's listing adds to what BioSpace has called a "cautiously optimistic" rebound for biopharma IPOs in 2026 after a prolonged drought in life-sciences listings. Other 2026 biotech debuts, tracked by BioSpace, give useful context for sizing Bambusa's raise:
- Seaport Therapeutics -- closed April 30 at roughly 14 million shares priced at $18 apiece.
- Aktis Oncology -- opened the year's IPO class on January 9.
- Eikon Therapeutics -- an upsized offering later in the year.
At $168.9 million, Bambusa's raise sits toward the smaller end of this year's biotech IPO cohort, consistent with its earlier-stage pipeline relative to those peers.
What to watch next
The key near-term signal is where BBTX trades once it opens on Nasdaq -- a first-day pop would reinforce the narrative, tracked across Pulse's sector coverage, of a genuine biotech IPO window reopening, while a flat or negative debut would suggest investors are still discriminating sharply by pipeline stage. Watch also for Bambusa's progress toward a Phase 2b trial of a subcutaneous formulation of BBT001, which the company has said it plans to begin preparing by the end of 2026.
The risk investors are underwriting is standard for clinical-stage biotech: Bambusa has no approved products and its most advanced asset, BBT001, remains in Phase 1 testing, meaning years and significant additional capital likely stand between this IPO and any potential commercial revenue.